Organovo Holdings, a developer and manufacturer of 3D human tissue for medical research and medical devices, is working with cloud design and technology software vendor Autodesk to develop the first biometric printing 3D design software.
According to Cris Frangold's review article published by the well-known investment website Seekingalpha, 3D printing technology has become one of the hottest new technologies. The potential for 3D bioprinting technology is very promising. In a few years, it will achieve rapid growth and generate large amounts of income.
The software will be used with Organovo's NovoGen MMX bioprinter, demonstrating that humans have taken an important step forward in improving the usability and functionality of 3D human tissue designs, potentially expanding the number of bioprinters. Organovo's 3D bioprinting technology can create 3-dimensional human tissues that structurally correct and constitute human cells. Organizations created in this way can function as if they were native human tissues. This also provides opportunities for advanced drug discovery and development. It may also be applied to clinical treatment and tissue transplantation in the future.
Autodesk is committed to developing the most advanced technologies such as human-computer interaction, computer graphics and digital design. It intends to apply its technology to the development of software for the design and simulation of molecular and human systems.
What is 3D bioprinting?
Organovo is exploring new ways of printing human tissue using materials that can produce body components, as well as human tissue transplantation using computerized adaptive manufacturing processes. Custom samples and finished products are produced using inexpensive 3D computer printers. Instead of using extruded plastic, metal, or ceramic materials, these medical printers use living cell materials. This process is called rapid bioprinting. It is an innovative application of the standard technology that we are familiar with with traditional inkjet printers. These printers can create any shape of tissue structure, such as blood vessels, small pieces of skin and muscle, and so on.
Synergy between Organovo and Autodesk
The two companies have great potential for cooperation. Organovo's NovoGen MMX Bioprinter is a new, fully automated (customized graphical user interface) software and hardware platform developed specifically to meet the diverse needs of biological research and bioprinting. From a hardware point of view, it is a powerful tool that uses the latest technology, but it runs on the latest software platform. Every time scientists want to use a printer, they must write relevant software from scratch, which means that scientists spend a lot of time debugging software instead of doing technical research.
Autodesk has become a leader in many professional design fields. All products that may have been developed in the past 20 years are developed using Autodesk software, but this will be the first time it has developed to create living things. software. The first application to be implemented in the next five years is likely to be a simple organization ready for clinical trials. At the same time, Organovo hopes to obtain a stable and sustainable source of income through the production of living organisms that can be used for drug research, discovery and development.
The development potential of 3D bioprinting technology
Demand for 3D Bioprinting Technology (Tencent Technology Co., Ltd.)
The best way to understand the potential of 3D bioprinting is to compare the evolution of other technologies that may have been completely unthinkable 20 years ago. Although the technology is different, it can still explain the problem. For example, the most typical example is the development of tablet computers and smart phones. The main driving force for the development of tablet and smart phone technology may be that consumers need a multifunctional, inexpensive, and practical portable device. Microsoft took the lead in introducing the commercial tablet PC Microsoft Tablet PC in 2002, but it did not get the success that Microsoft hoped. Eight years later, Apple launched iPad in 2010, which broke the technical barriers. Tablet PCs are now selling well in the global market, and it is expected that its sales will soon surpass notebooks.
The development of 3D printing technology has become one of the hottest new technologies today. 3D printing technology can be traced back to 1984. This technology continues to advance in accordance with Moore's Law, while the cost continues to drop, gradually reducing the extent to which mainstream companies can use 3D printers. In the past two years, the market leaders in 3D printing, 3D Systems and Stratasys, have been the two most popular companies. 3D printing companies have been developing rapidly in recent years. The 3D printer is expected to be the hottest topic at the Las Vegas CES show in early January this year. 3D Systems' shares have risen by 15% since the beginning of the year.
It is expected that the 3D printing industry will achieve rapid growth and generate substantial revenue in recent years as more and more companies begin to adopt this technology. Today, industry giants such as Ford, Boeing and General Electric have begun adopting 3D printing technology in their manufacturing processes.
According to Autodesk vice president Brian Mathews, "3D printing is a way to re-imagine the manufacturing process." Ford used 3D printing technology to increase the speed and cost-effectiveness of sample manufacturing. Similarly, Boeing applied 3D printing technology to the manufacture of components for military aircraft. In November 2012, General Electric acquired Morris Technologies, an engineering technology company that has invested heavily in 3D printing equipment. It will focus on printing the various components of the latest jet engine.
It is not hard to imagine that human tissue 3D printing technology will likely develop with similar growth trends.
According to Donate Life America, a non-profit organization in the United States that works to increase the donation of human organs, eyes, and tissues, "Although medical technology and donations have been developing, the market demand for human organs, eyes and tissues is still far greater than donations. In the United States alone, more than 115,000 people are waiting for organ transplants."
CompaniesandMarkets.com is a global business information integrator, which has many expert analysts who have compiled hundreds of market research reports.
According to an expert named Mike King, “The global artificial organ market is expected to reach US$20 billion by 2017. This is mainly due to the increasing demand from patients who need organ transplants. In addition, technological advances, reduced costs, an aging population, and a small number of donated organs are also factors that will increase the market demand for artificial organs in the coming years."
The report also pointed out that due to the global diabetes patients exceed 100 million people, it is expected that the artificial pancreas will have a good development prospects. The global demand for artificial organs is caused by artificial kidneys.
in conclusion
Other companies are also actively researching and developing organizational rebirth and therapeutic technologies, such as Tengion, but they use traditional technologies instead of bioprinting technologies; the focus of those companies is different from that of Organovo. It may take a long time for the 3D printing technology to make a profit. Although the investment risk in this technology area is high, the potential return may be very large.
However, there are also some short-term positive factors in this technology area, such as income from drug discovery and development. In 2010, Organovo signed a cooperation agreement with Pfizer. It is expected that Organovo will receive 450,000 U.S. dollars in revenue before the end of 2012. Later, in October 2011, it also reached a 30-month cooperation with United Therapeutics. Organovo will use its bioprinting technology to conduct studies related to pulmonary hypertension treatment. Organovo has admitted that it has received $618,000 in revenue from this cooperation.
(Editor)
Foshan Gruwill Hardware Products Co., Ltd. , https://www.gwwirebasket.com